Clinical Trials Logo

Contact Dermatitis clinical trials

View clinical trials related to Contact Dermatitis.

Filter by:

NCT ID: NCT03089775 Completed - Contact Dermatitis Clinical Trials

Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis

BBI
Start date: March 14, 2017
Phase: Phase 1
Study type: Interventional

This two cohort study (Cohort A and B) is being conducted to assess the safety and efficacy of BBI-2000 for the prevention (Cohort A) and treatment (Cohort B) of delayed type hypersensitivity reaction.

NCT ID: NCT02700373 Completed - Contact Dermatitis Clinical Trials

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

Start date: March 2016
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.

NCT ID: NCT02028208 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study

Start date: November 4, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the diagnostic performance and safety of ascending doses of mercury, aluminum and palladium metal allergens proposed for inclusion in a metal allergen panel. Optimal dose will be selected based on the lowest dose of each allergen eliciting a positive response in 70-90% of subjects tested.

NCT ID: NCT02028182 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of Lyral® Dose Response Study

Start date: February 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine optimal allergen dose as the lowest concentration eliciting positive reactions in 70-90% of subjects. Frequency of positive, negative, doubtful and irritant reactions, and concordance with a corresponding reference allergens will be captured.

NCT ID: NCT02026700 Not yet recruiting - Contact Dermatitis Clinical Trials

Bariederm Cream in Chronic Contact Dermatitis

Start date: February 2014
Phase: N/A
Study type: Interventional

We intend to evaluate the efficiency and tolerability of a barrier cream (bariederm) in protecting hands of individuals with hand dermatitis, either due to allergy or irritation. We believe that the use of the cream would benefit with the skin.

NCT ID: NCT01518348 Withdrawn - Contact Dermatitis Clinical Trials

Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents

PREAII
Start date: December 2012
Phase: Phase 3
Study type: Interventional

To evaluate the diagnostic performance (primary) and safety (secondary) of seven T.R.U.E. Test Panel 3.2 allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol in pediatric subjects 6-18 years of age with suspected contact dermatitis based on symptoms and clinical history.

NCT ID: NCT00824889 Completed - Melanoma Clinical Trials

Exploratory Study of Natural Killer Cells in Human Skin

Start date: February 2009
Phase: N/A
Study type: Interventional

Natural Killer (NK) cells play a unique role during innate immune responses as they are able to recognize and eliminate, without specific sensitization, tumors, microbe-infected cells as well as allogeneic cells.In a first time, we will characterize the tissue distribution, the phenotype and the effector functions of NK cells present in the human healthy skin.

NCT ID: NCT00646867 Completed - Contact Dermatitis Clinical Trials

Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis

Start date: February 2008
Phase: N/A
Study type: Interventional

To determine if Tetrix Cream, when applied to the skin lesions on patients with contact dermatitis, improves the symptoms of burning and itching.

NCT ID: NCT00640614 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

Start date: April 2008
Phase: Phase 3
Study type: Interventional

We propose an open, prospective, multi-center Phase III study to evaluate the diagnostic performance and safety of seven new T.R.U.E. Test allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol.Allergen performance and safety will be evaluated in adult patients with suspected contact dermatitis, and in adult patients with a known or suspected sensitization to at least one of the seven allergens.

NCT ID: NCT00640250 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response

Start date: April 2008
Phase: Phase 2
Study type: Interventional

We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").